Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Other Financing Activities
Financing cash flows not reported separately.
AlvotechNASDAQ: ALVO
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns negative
Q1 FY2026 other financing activities was -$2.25M, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$9.26M.
Context
- Other financing activities amounted to 1.8% of revenue in FY2025, up 0.7 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near -$2.25M or moves back toward the trailing-twelve-month quarterly average of -$2.32M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (10.37M) USD
- Year-over-year change
- -102.1%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.37M) | -102.1% |
| FY2024 | 2024-12-31 | (5.13M) | +24.1% |
| FY2023 | 2023-12-31 | (6.76M) | -104.3% |
| FY2022 | 2022-12-31 | 157.27M | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Financing Activities vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's LTM Mar 2026 other financing activities of $9.26M is the 9th largest of the 11 companies compared; the peer median is $18.43M.
- Its year-over-year change of +119.0% is the 4th highest of 10, against a peer median of -51.1%.
- Other financing activities amounts to 1.7% of revenue for ALVO, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.72B | +307.5% | -71.5% | 11.1% | |
| LTM Jun 2026 | $1.03B | +12844.4% | +266.2% | 10.4% | |
| LTM Jun 2026 | $157M | -96.4% | -20.4% | 0.4% | |
| LTM Jun 2026 | $78.41M | +36.6% | -4.4% | 2.5% | |
| LTM Jun 2026 | $74.36M | +120.4% | +41.9% | 0.4% | |
| LTM Mar 2026 | $44.47M | -4656.4% | — | 6.2% | |
| LTM Mar 2026 | $24.69M | -51.1% | — | 3.1% | |
| LTM Mar 2026 | $12.17M | -2165.4% | +374.7% | 4.5% | |
| LTM Mar 2026 | $9.26M | +119.0% | — | 1.7% | |
| LTM Sep 2026 | $8M | — | -24.6% | 0.1% | |
| LTM Mar 2026 | $0 | -100.0% | -4.7% | 0.0% | |
| Peer median (excluding ALVO) | $18.43M | -51.1% | -4.6% | 2.8% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.5M) | (513.58M) | (551.73M) | (231.86M) | 27.92M |
| Depreciation & Amortization | 18.2M | 20.41M | 24.21M | 31.3M | 37.85M |
| Deferred Income Tax | (47.69M) | (38.07M) | (99.32M) | 14.3M | 108.43M |
| Stock-Based Compensation | 0 | 10.32M | 18.03M | 7.63M | 17.38M |
| Change in Working Capital | (6.81M) | (47.89M) | 26.33M | (288.64M) | (117.64M) |
| Accounts Receivables | (13.53M) | (13.23M) | (24.83M) | (164.24M) | (6.33M) |
| Inventory | (29.41M) | (32.41M) | (11.3M) | (49.97M) | (90.13M) |
| Accounts Payables | 14.32M | 0 | 0 | 0 | (21.18M) |
| Other Working Capital | 21.81M | (2.25M) | 62.46M | (74.44M) | 0 |
| Other Non-Cash Items | (90.36M) | 256.42M | 270.29M | 230.44M | (124.14M) |
| Operating Cash Flow | (228.17M) | (312.39M) | (312.19M) | (236.84M) | (50.2M) |
| Capital Expenditures | (40.63M) | (49M) | (46.47M) | (57M) | (64.47M) |
| Acquisitions (Net) | 0 | 0 | 0 | 12M | (14.04M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (31.66M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 5.95M |
| Other Investing Activities | (20.17M) | (25.66M) | (13.11M) | 22.79M | 0 |
| Investing Cash Flow | (40.63M) | (63.54M) | (46.34M) | (18.87M) | (104.22M) |
| Debt Repayment | 68.98M | 257.82M | 171.2M | 151.98M | 202.48M |
| Common Stock Issued | 185.86M | 9.83M | 136.88M | 150.45M | 78.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 157.27M | (6.76M) | (5.13M) | (10.37M) |
| Financing Cash Flow | 254.83M | 424.91M | 301.32M | 297.31M | 270.83M |
| Effect of Forex Changes | (161K) | (113K) | 1.94M | (1.32M) | 4.51M |
| Net Change in Cash | (14.13M) | 48.87M | (55.27M) | 40.27M | 120.93M |
| Free Cash Flow | (268.8M) | (361.39M) | (358.66M) | (293.84M) | (114.67M) |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.